Related Experiment Video
Updated: Aug 29, 2026
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS)
Published on: March 17, 2012
An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole
M Riviere1, V Meininger, P Zeisser
1Benefit Canada Inc, Montreal, Quebec.
Background:
In an attempt to better understand and define the progression of amyotrophic lateral sclerosis (ALS), we developed a classification of 5 discrete health states that reflect patients' activities of daily living. These health states were used to determine whether patients with ALS who are treated with riluzole differed from those treated with placebo.
Setting:
Clinics for patients with ALS.
Design:
Placebo-controlled trial of riluzole treatment in 959 patients with ALS.
Interventions:
Treatment with riluzole or placebo. MAIN DEPENDENT MEASURES: A Cox model was used to assess whether, from the initial randomization to the end of an 18-month follow-up, there was a difference in the times of transition into subsequent health states between patients treated with riluzole and those treated with placebo.
Results:
Our analysis showed a significant difference in the time to transit between the riluzole and the placebo groups in less severely affected cases, ie, state 2 and state A (the milder states) of ALS.
Conclusion:
Patients receiving riluzole remained in the milder health states longer (P<.05).
More Related Videos
05:28Application of a Dual Upper Limb Task-Oriented Robotic System for the Functional Recovery of the Upper Limb in Stroke Patients
Published on: October 11, 2024
04:41Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
Published on: February 24, 2026
Related Concept Videos
01:20Comparing the Survival Analysis of Two or More Groups
01:21Cancer Survival Analysis